- HOME >
- GRADUATE >
- Human Sciences >
Hematology and Medical Oncology
| Master's Program | Human Sciences, Graduate School of Medicine |
|---|---|
| Doctor's Program | Medical Science Division, Department of Medical Science, Graduate School of Medicine, Science and Technology |
| Professor | MAKISHIMA Hideki (Hematology) |
|---|---|
| Associate Professor | KANDA Shintaro (Medical Oncology) |
| Senior Assistant Professor | NAKAZAWA Hideyuki (Hematology) |
| Assistant Professor | SAKAI Hitoshi (Hematology), NISHINA Sayaka (Hematology) |
E-mail ： makishimah(at)shinshu-u.ac.jp
※ Change (at) to @ when you send an e-mail.
We are engaged in cancer treatment, education and research. The Department of Medical Oncology provides drug therapy for cancers throughout the body and also deals with malignant tumors that are often difficult to diagnose and treat, such as rare cancers and cancers of unknown primary. We conduct cancer research from a cross-organ and bird's-eye viewpoint.
Our missions in hematology cover a wide spectrum of diseases and conditions from a common illness to a rare disease entity. During frequent encounters with patients challenging intractable end of the spectrum of hematological diseases at Shinshu University Hospital, we learn both intensive/aggressive treatment style for a cure of the disease and respectful/modest treatment style for enhancing the human dignity. We take best advantage of our teamwork for better treatment at the hospital and for deeper understanding of the disease at our laboratory.
It is a great pleasure to discover new findings in the field of cancer, an intractable disease. Clinical research in the field of cancer is often conducted at multiple institutions, and you will make friendships with researchers at other institutions in the course of such collaborative research.
Understanding the etiology and pathophysiology of a disease may lead to development of diagnosis and novel therapies. We believe that studying each case carefully is necessary for a clinician to unravel the complexity of the disease and to move into a new paradigm. It’d be a thrill and excitement for our team that you join us to feel such dynamism in your research and clinical work every day.
1. Araki T, Kanda S, Ide T, Sonehara K, Komatsu M, Tateishi K, Minagawa T, Kiniwa Y, Kawakami S, Nomura S, Okuyama R, Hanaoka M, Koizumi T. Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients. ESMO Open 8 (6): 102030, 2023, PMID: 37852033
2. Kobayashi T, Nishino Y, Takiguchi T, Kanda S, Otsuki K, Tanaka Y, Nakazawa Y, Ito K, Hayashi R, Yasumoto K, Uramoto H, Hirono Y, Makino T, Nakada M, Yano S, Koizumi T. Epidemiological and therapeutic profiles of lung cancer patients in the Hokushin Region Japan: a retrospective hospital administrative database study. BMC Pulm Med 23 (1): 322, 2023, PMID: 37658334
3. Atagi T, Kanda S, Kawakami H, Kobayashi T, Koizumi T. Pleomorphic Liposarcoma Initially Presenting with Multiple Organ Involvement Including the Heart. Intern Med, Online ahead of print, 2023, PMID: 37495537
4. Araki T, Kanda S, Komatsu M, Sonehara K, Tateishi K, Takada M, Kato A, Yamamoto M, Nishie K, Hama M, Agatsuma T, Kakizaki Y, Yoshiike F, Matsuo A, Chiaki T, Samizo K, Takagi Y, Yamaura M, Hanaoka M, Koizumi T. Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study). Transl Lung Cancer Res 12 (6): 1320-1327, 2023, PMID: 37425417
1. Nakazawa H, Sakai K, Ohta A, Fujishima N, Matsuda A, Hosokawa K, Nakamura F, Nakao S, Mitani K, Ishida F. Incidence of Acquired Pure Red Cell Aplasia: A Nationwide Epidemiologic Analysis With 2 Registry Databases in Japan. Blood Adv 6(24): 6282-6290, 2023, PMID: 35522950
2. Kawakami T, Nakazawa H, Ishida F. Somatic mutations in acquired pure red cell aplasia. Seminars in Hematology 59(3): 131-136, 2022, PMID: 36115689
3. Nakazawa H, Kaiume H, Igarashi K, Yamazaki T, Umemura T, Asano N, Uehara T, Ishida F. A Diagnostic Impact of Serum Autotaxin Levels in Patients with Bone Marrow Fibrosis. Clinical Lymphoma, Myeloma and Leukemia 23(2): e117-e124, 2022, PMID: 36567212
4. Nishina S, Sakai H, Sakai K, Kawakami T, Kawakami F, Matsuzawa S, Ito T, Nakazawa H. Attaining Complete Remission May Confer a Better Outcome after Allogeneic Hematopoetic Stem Cell Transplantation in Adult Patients with Acute B-cell Lymphoblastic Leukemia. Shinshu Medical Journal 71(5): 257-267, 2023
5. Kobayashi S, Biyajima K, Matsuzawa S, Sakai K, Kawakami F, Kawakami T, Nishina S, Sakai H, Fuseya C, Nakazawa H. Acute leukemias in pregnant women: Resultes of a retrospective study at a local tertiary-care hospital in Japan. eJHaem 4(2): 393-400, 2023, PMID: 37203296
